B
Biohaven Ltd. (BHVN)
NYQ – Real vaqt narxi. Valyuta: USD
14.50
+0.01 (0.07%)
Bozor ochiq: Aug 12, 2026, 12:50 PM EDT
14.21
-0.28 (-1.93%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NYQ – Real vaqt narxi. Valyuta: USD
14.50
+0.01 (0.07%)
Bozor ochiq: Aug 12, 2026, 12:50 PM EDT
14.21
-0.28 (-1.93%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
Biohaven Ltd., biotexnologiya kompaniyasi, dunyo bo'ylab immunologiya, nevrologiya va onkologiya terapevtik sohalarida davolash usullarini kashf qilish, ishlab chiqish va tijoratlashtirishga qaratilgan. Kompaniya Graves kasalligi va revmatoid artritni davolash uchun 2-bosqich klinik sinovlarida bo'lgan BHV-1300; IgA nefropatiyasini davolash uchun 2-bosqich klinik sinovlarida bo'lgan BHV-1400; peripartum kardiomiopatiyasini davolash uchun 1-bosqich klinik sinovlarida bo'lgan BHV-1600; Parkinson kasalligini davolash uchun 3-bosqich klinik sinovlarida bo'lgan BHV-8000; fokal epilepsiyani davolash uchun 3-bosqich klinik sinovlarida bo'lgan Opakalim; og'riqni davolash uchun 2-bosqich klinik sinovlarida bo'lgan BHV-2100; va semirishni davolash uchun 2-bosqich klinik sinovlarida bo'lgan BHV-2000 ni ishlab chiqadi. Kompaniya, shuningdek, rivojlangan yoki metastatik epiteliya o'smalarini davolash uchun 2-bosqich klinik sinovlarida bo'lgan BHV-1510; va urothelial saraton va boshqa o'smalarni davolash uchun 2-bosqich klinik sinovlarida bo'lgan BHV-1530 ni ishlab chiqmoqda. Bundan tashqari, uning preklinik mahsulot quvurlari orasida miasteniya gravisni davolash uchun BHV-1310; immun vositali kasalliklarni davolash uchun BHV-1320; Pemphigus, MuSK MG va LGI-1 Ensefalitni davolash uchun BHV-1450; membranli nefropatiyani davolash uchun BHV-1420; Graves kasalligi va TED ni davolash uchun BHV-1440; 1-toifa diabetni davolash uchun BHV-6500; IgM nefropatiyasi va Waldenstrom's ni davolash uchun BHV-1490; neyrodegenerativ kasalliklarni davolash uchun BHV-8100; va tinnitusni davolash uchun BHV-1955 mavjud. Kompaniya ilgari Biohaven Research Ltd. nomi bilan tanilgan va 2022 yil sentyabr oyida Biohaven Ltd. nomini o'zgartirgan. Biohaven Ltd. 2022 yilda tashkil etilgan va shtab-kvartirasi Nyu-Xeyven, Konnektikutda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Bruce D. Car D.V.M., DACVP, Ph.D. | Chief Innovation Officer |
| Dr. Vladimir Coric M.D. | Chairman & CEO |
| Mr. Clifford Bechtold M.S. | President & GM of Biohaven Ireland Chief Compliance Officer |
| Mr. George C. Clark CPA | VP & Chief Accounting Officer |
| Mr. John McGill | Chief Technology Officer |
| Mr. Matthew Buten | Chief Financial Officer |
| Mr. Warren Volles J.D. | General Counsel & Chief Legal Officer |
| Ms. Deb Young | Senior Director of Regulatory Affairs & Operations |
| Ms. Jennifer Porcelli | Vice President of Investor Relations |
| Ms. Kimberly Gentile | Senior Vice President of Clinical Operations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-10 | 8-K | bhvn-20260810.htm |
| 2026-08-10 | 10-Q | bhvn-20260630.htm |
| 2026-08-07 | 8-K | bhvn-20260803.htm |
| 2026-07-09 | 8-K | bhvn-20260709.htm |
| 2026-05-27 | 8-K | bhvn-20260526.htm |
| 2026-05-05 | 8-K | bhvn-20260504.htm |
| 2026-05-04 | S-3ASR | biohavens-3asr.htm |
| 2026-05-04 | 8-K | bhvn-20260428.htm |
| 2026-03-13 | DEFA14A | a2026bhvndefa14aproxynotice.htm |
| 2026-03-13 | DEF 14A | bhvn-20260313.htm |